KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Total Liabilities (2016 - 2025)

Idexx Laboratories has reported Total Liabilities over the past 17 years, most recently at $1.7 billion for Q4 2025.

  • Quarterly results put Total Liabilities at $1.7 billion for Q4 2025, up 2.78% from a year ago — trailing twelve months through Dec 2025 was $1.7 billion (up 2.78% YoY), and the annual figure for FY2025 was $1.7 billion, up 2.78%.
  • Total Liabilities for Q4 2025 was $1.7 billion at Idexx Laboratories, down from $1.8 billion in the prior quarter.
  • Over the last five years, Total Liabilities for IDXX hit a ceiling of $2.2 billion in Q3 2022 and a floor of $1.6 billion in Q1 2021.
  • Median Total Liabilities over the past 5 years was $1.8 billion (2023), compared with a mean of $1.8 billion.
  • Biggest five-year swings in Total Liabilities: skyrocketed 32.74% in 2022 and later decreased 17.36% in 2023.
  • Idexx Laboratories' Total Liabilities stood at $1.7 billion in 2021, then rose by 22.37% to $2.1 billion in 2022, then dropped by 16.96% to $1.8 billion in 2023, then fell by 4.35% to $1.7 billion in 2024, then rose by 2.78% to $1.7 billion in 2025.
  • The last three reported values for Total Liabilities were $1.7 billion (Q4 2025), $1.8 billion (Q3 2025), and $1.9 billion (Q2 2025) per Business Quant data.